Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
-
1681
-
1682
a, Anti-correlation of gene expression between <i>dmdR1</i> and its predicted regulon. Left: Pearson correlation coefficients (PCCs) between <i>dmdR1</i> and all genes with a DmdR1 position weight matrix (PWM) score greater than 15 in their regulatory region. The vertical dashed line marks the refined PWM score threshold of 22.875....
Published 2025“…Left: Pearson correlation coefficients (PCCs) between <i>dmdR1</i> and all genes with a DmdR1 position weight matrix (PWM) score greater than 15 in their regulatory region. The vertical dashed line marks the refined PWM score threshold of 22.875. …”
-
1683
Summary of study eligibility criteria.
Published 2025“…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”
-
1684
Summary of study participation and feasibility.
Published 2025“…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”
-
1685
-
1686
-
1687
-
1688
-
1689
-
1690
-
1691
-
1692
-
1693
-
1694
-
1695
-
1696
-
1697
-
1698
-
1699
-
1700